

LIVE SIMULCAST

ABIM
CME MOC

2019 MSK CARDIO-ONCOLOGY SYMPOSIUM



LIVE SIMULCAST
MAY 17-18, 2019



Memorial Sloan Kettering
Cancer Center

OVERVIEW

Cardio-oncology is a burgeoning field that has great importance as newly developed cancer treatment improve cancer survival. With novel treatments come new or unexpected cardiovascular toxicities as many cancer survivors are now living enough to experience the potential cardiotoxic effects of these treatments.

The purpose of this conference is to provide a state-of-the-art, comprehensive, case-based curriculum that addresses important clinical topics relevant to the cardiovascular health of patients with cancer. Clinical experts from Memorial Sloan Kettering Cancer Center and around the country will present an up-to-date overview on cutting edge cancer therapies and best practice strategies in the evaluation and management of heart disease in cancer patients from early diagnosis, treatment and long-term surveillance. All presentations will include devoted time to permit interaction between audience members and presenters.

This course is intended for cardiologists, internists, hematologists/ oncologists and other affiliated healthcare professionals who are involved in the care of cancer patients or have a special interest in this area.

LIVE SIMULCAST *

We are pleased to offer a live simulcast for the 2019 MSK Cardio-Oncology Symposium. Attendees registered for the live simulcast option will receive detailed instructions via email prior to the start of the course. This will include information on how to engage with the faculty (through an online Q&A) as well as information on how to claim CME and ABIM MOC credits - active participation throughout the live simulcast is required

*This live broadcast is for streaming use only. By watching this Simulcast you acknowledge that Memorial Sloan Kettering Cancer Center retains all rights, titles and interest in to all copyrights, trademarks, trade secrets, patents and any other proprietary rights to the content of this material. You are not authorized to record this event. You agree to prevent any unauthorized copying, recording, use, distribution and/or re-broadcast of this live simulcast.

Educational Objectives


- Describe the cardiotoxic regimens used in cancer treatment including novel targeted therapies
- Identify patients at high cardiovascular risk prior to planned oncologic treatment
- Construct cardioprotective strategies prior, during and after cancer therapy
- Explain the principles of surveillance and the incorporation of current guidelines on cardiotoxicity monitoring into clinical practice.
- Describe primary and secondary prevention of cardiotoxicity
- Explain the appropriate use of non-invasive imaging modalities for cardiotoxicity monitoring; the strengths and weaknesses of each modality including echocardiography, MUGA, CMR and CTA.
- State the late cardiovascular sequelae of cancer and its treatment
- Describe the importance of the multi-disciplinary cardio-oncology team



Memorial Sloan Kettering
Cancer Center

mskcc.org/Cardio-Onc

MSK COURSE DIRECTORS



Jennifer Liu, MD

Director, Cardiovascular Laboratories
Attending Physician
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College



Richard M. Steingart, MD

Chief, Cardiology Service
Attending Physician,
Memorial Sloan Kettering Cancer Center
Professor of Medicine,
Weill Cornell Medical College

Symposium Highlights

- **Clonal Hematopoiesis of Indeterminate Potential (CHIP):** A New Cardiovascular Risk Factor?
- **Breast cancer treatment:** Contemporary best practice strategies in cancer treatment, cardiotoxicity monitoring and management.
- **Immunotherapy:** Understanding cutting edge check-point inhibitor and CAR-T cell therapy with a detailed discussion of their cardiovascular effects
- **Novel oncologic therapy and emerging cardiotoxicity:** Recognizing the potential cardiac effects of new targeted therapy
- **Cardiac amyloidosis:** Contemporary approach to diagnosis and advances in treatment.
- **Radiation-Induced Heart Disease:** Understanding the practice change over time; monitoring and management of CV side effects.
- **Cardiovascular risk assessment:** Primary and secondary cardiovascular risk reduction during and after cancer therapy.
- **Cardiac Imaging:** Which modality, how often and which patient? Optional hands-on workshop on GLS measurement by 2D STE.
- **Vascular complications:** Toxicity related to cancer treatment. Management of arterial and venous thromboembolism in cancer.
- **Clinical Challenges:**
 - 5FU induced chest pain
 - Cardiovascular considerations in bone marrow transplant
 - Atrial fibrillation and anticoagulation
 - Surgical clearance
 - Pharmacologic, surgical and interventional cardiac approaches to acute coronary syndromes, valvular disease and arrhythmias
 - Stroke in cancer patients
- **Survivorship:** Diagnosis, prevention and management of CV disease in cancer survivors
- **Establishing a cardio-oncology program:** Identifying the stakeholders
- **How to Code and Bill for Cardio-Oncology**

COURSE FACULTY

MSK Course Faculty

Oren Cahlon, MD

Radiation Oncology

Angel Chan, MD, PhD

Cardiology Service

Carol Chen, MD

Cardiology Service

Chau Dang, MD

Breast Oncology Service

Sergio A. Giralt, MD

Bone Marrow Transplant Service
Myeloma Service

Dipti Gupta, MD, MPH

Cardiology Service

Bhisham Harchandani, MD

Cardiology Service

Michelle Johnson, MD, MPH

Cardiology Service

Invited Course Faculty

Gregory Armstrong, MD, MSCE

St. Jude Children's Research Hospital

Anita Arnold, DO, MBA

Lee Physician Group

Ana Barac, MD, PhD

MedStar Washington Hospital Center

Usman Baber, MD

Mt. Sinai Hospital

Jim Cheung, MD

Weill Cornell Medical Center

Marielle Scherrer Crosbie, MD, PhD

Perelman School of Medicine
University of Pennsylvania

Susan Dent, MD

Duke University

Michael Fradley, MD

University of South Florida

Joerg Herrmann, MD

Mayo Clinic, Rochester NY

Bonnie Ky, MD, MSCE

Perelman School of Medicine
University of Pennsylvania

Heather J. Landau, MD

Bone Marrow Transplant Service
Myeloma Service

Katherine Lee-Chuy MD

Cardiology Service

Elena Mead, MD

Critical Care Medicine Service

Michael Postow, MD

Melanoma Service

Wendy Schaffer, MD, PhD

Cardiology Service

Gerald Soff, MD

Benign Hematology Service

Emily S. Tonorezos, MD, MPH

General Internal Medicine Service

Anthony Yu, MD

Cardiology Service

Daniel Lenihan, MD

Washington University

Steven E. Lipshultz, MD, FAAP, FAHA

University at Buffalo Jacobs School of
Medicine and Biomedical Sciences
John R. Oishei Children's Hospital

Bruce Lytle, MD

The Heart Hospital Baylor Plano

Peter Libby, MD

Brigham and Women's Hospital

Syed Mahmood, MD

Weill Cornell Medical Center

Javid Moslehi, MD

Vanderbilt University Medical Center

Babek Navi, MD

Weill Cornell Medical Center

Vera Potievskaya, MD, PhD

National Medical Research Radiology Center

Alex Reyentovich, MD

NYU Langone Health

Jonathan Weinsaft, MD

Weill Cornell Medical Center

SYMPOSIUM SCHEDULE

Friday, May 17, 2019 All times are Eastern Standard Time (EST)

Department of Medicine Grand Rounds	
8:00 AM	Welcome & Introduction Jennifer Liu, MD
8:05 AM	Opening Remarks Richard M. Steingart, MD
8:15 AM	From Bench to Bedside Clonal Hematopoiesis of Indeterminate Potential (CHIP): A New Risk Factor of Cardiovascular Disease? Peter Libby, MD
8:40 AM	Keynote Lecture Cardio-Oncology – Past, Present and Future Susan Dent, MD
9:00 AM	Q&A

SESSION I
Best Practice Strategies to Optimize Outcomes

9:10 AM	Cardio-Oncology Clinical Practice Guidelines: Key Take Home Messages Ana Barac, MD, PhD
Breast Cancer:	
9:30 AM	Contemporary Breast Cancer Therapy – Anthracyclines, HER2 targeted therapy and Other Treatments Chau Dang, MD
9:50 AM	Cardiotoxicity Associated with Breast Cancer Treatment: Risk Prediction and Preventative Strategies Anthony Yu, MD
10:10 AM	Managing CV issues During and After Breast Cancer Treatment – Case Review Michelle Johnson, MD, MPH
10:25 AM	Q&A
10:40 AM	Break

Immunotherapy:	
11:00 AM	Immunotherapy: Understanding Antitumor Immunity and Moving the Field Forward Michael Postow, MD
11:20 AM	CAR T-cell Therapy: What, How, For Whom? Understanding the Potential Toxicities Elena Mead , MD
11:40 AM	Immunotherapy Associated Myocarditis – Detection and Treatment Strategies Javid Moslehi, MD
12:00 PM	Case Review Carol Chen, MD
12:15 PM	Q&A

12:35 PM	Lunch Break
LUNCH SYMPOSIUM Amyloidosis and Multiple Myeloma Contemporary Diagnosis and New Advances in Treatment	
12:55 PM	Cardiac Amyloidosis: Epidemiology, Presentation, Diagnosis Jennifer Liu, MD
1:15 PM	Contemporary Management of AL amyloidosis Heather J. Landau, MD
1:35 PM	Emerging Treatments for TTR Cardiac Amyloid Alex Reventovich, MD
1:55 PM	Treatment of Multiple Myeloma – Cardiac Safety with Proteasome and Immunomodulatory Drugs Daniel Lenihan, MD
2:15 PM	Q&A
2:30 PM	Break

SESSION II
Vascular Complications in Patients with Cancer

2:40 PM	Venous Thromboembolism in Cancer Patients: Prevention and Treatment. Gerald Soff, MD
3:00 PM	VSPI and Adverse Cardiovascular Effects – HTN, LV Dysfunction and Thromboembolism. Daniel Lenihan, MD
3:20 PM	Chemotherapeutic Agents Associated Coronary Ischemia Wendy Schaffer, MD PhD
3:40 PM	Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients Dipti Gupta, MD, MPH
4:00 PM	Q&A
4:20 PM	Break

SESSION III
Cancer Survivorship

4:35 PM	Late Onset Cardiotoxicity in Adult Survivors of Childhood Cancer: Incidence, Risk Factors and Individual CV Risk Prediction Gregory Armstrong, MD, MSCE
4:55 PM	How to Mitigate Cardiotoxicity – Role of Exercise, Statin and Cardioprotective Agents. Lessons Learned from Survivors of Childhood Cancer. Steven E. Lipshultz, MD, FAAP, FAHA
5:15 PM	Cancer Survivorship Clinic: Essential Components of Care Emily S. Tonorezos, MD, MPH
5:35 PM	Q&A
5:55 PM	Special Lecture The QT Interval Conundrum in Patients with Cancer. How to and Why Measure QT Interval? Michael Fradley, MD
6:15 PM	Q&A
6:20 PM	Adjourn

SYMPOSIUM SCHEDULE

Saturday, May 18, 2019

- 7:50 AM **Opening Remarks/Day 1 Review**
Jennifer Liu, MD
Richard M. Steingart, MD
- 8:00 AM **Keynote Lecture**
My Vision for the Future of JACC: CardioOncology as the Editor-in-chief
Bonnie Ky, MD, MSCE

SESSION IV Imaging in Cardio-Oncology/Preclinical Markers of Cardiotoxicity

MODERATOR Angel Chan, MD, PhD

- 8:20 AM **Role of Echo in Clinical Decision Making for Patients During and After Cancer Therapy**
Jennifer Liu, MD
- 8:40 AM **Is 2D Echo LVEF Enough? The Role of Serum Biomarker, Strain Imaging, 3D Echo and Cardiac MRI**
Marielle Scherrer Crosbie, MD, PhD
- 9:00 AM **Multimodality Imaging of Cardiac Masses**
Jonathan Weinsaft, MD
- 9:20 AM **Q&A**

SESSION V Cardiovascular Considerations in Hematologic Malignancies

- 9:40 AM **Understanding Stem Cell/Bone Marrow Transplant**
Sergio A. Giralt, MD
- 10:00 AM **Common CV Issues Encountered during Bone Marrow Transplant**
Wendy Schaffer, MD PhD
- 10:20 AM **TKI Associated CV Toxicity in CML**
Joerg Herrmann, MD
- 10:40 AM **Q&A**

11:00 AM **Break**

SESSION VI Cardiovascular Challenges in Cancer Patients

- 11:20 AM **CLINICAL CONUNDRUMS**
Medical and Interventional Management of Acute and Chronic CAD
Usman Baber, MD
AF and Anticoagulation - Does the CHADS Score Apply
Jim Cheung, MD
Stroke in Patients with Cancer
Babek Navi, MD
- 12:20 PM **Q&A**
- 12:40 PM **Lunch**

SESSION VII Radiation and the Heart

MODERATOR Vera Potievskaya, MD, PhD

- 1:20 PM **Radiation Therapy. Strategies to Minimize Radiation Induced Cardiotoxicity - Past, Present and Future**
Oren Cahlon, MD
- 1:40 PM **Cardiovascular Complications of Radiation**
Richard M. Steingart, MD
- 2:00 PM **Cardiac Surgery in Patients with Radiation Associated Heart Disease**
Bruce Lytle, MD
- 2:20 PM **Q&A**

SESSION VIII Challenging Real-World Cases - Discussion with the Experts

- 2:40 PM **MODERATOR**
Carol Chen, MD
- PRESENTERS**
Syed Mahmood, MD
Katherine Lee-Chuy, MD
Bhisham Harchandani, MD
- EXPERT PANEL**
Susan Dent, MD
Joerg Herrmann, MD
Richard M. Steingart, MD

3:40 PM **Special Lecture**
How to Code and Bill for Cardio Oncology
Anita Arnold, DO, MBA

4:00 PM **Q&A**

4:05 PM **Closing Remarks and Adjourn**



Memorial Sloan Kettering
Cancer Center

mskcc.org/Cardio-Onc

REGISTRATION

Live Simulcast Registration Fee

\$725

Register Online:
mskcc.org/Cardio-Onc

You will receive detailed instructions via email prior to the start of the course. This will include information on how to engage with the faculty as well as information on how to claim CME credits - active participation throughout the live simulcast is encouraged. For inquiries regarding the simulcast, please email cme@mskcc.org.

- **MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners.** If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- **MSK employee registration is complimentary.** However, you must complete course registration in order to attend this course.

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **16.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **16.50 Medical Knowledge MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.